Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kane Biotech Inc. V.KNE

Alternate Symbol(s):  KNBIF

Healthcare Biotechnology
Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. It has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its... see more

Recent & Breaking News (TSXV:KNE)

Kane Biotech Announces Closing of Private Placement

GlobeNewswire May 17, 2022

Kane Biotech (TSXV:KNE) to close fully subscribed private placement

Trevor Abes  May 6, 2022

Kane Biotech Announces Update on Private Placement

GlobeNewswire May 6, 2022

Kane Biotech Announces Extension of Private Placement Offering

GlobeNewswire April 29, 2022

Kane Biotech's (TSXV:KNE) joint venture receives certification, triggering $1.3M in milestone payments

Caroline Egan  April 7, 2022

IIROC Trading Resumption - KNE

Canada NewsWire April 7, 2022

STEM Animal Health Awarded Veterinary Oral Health Council (VOHC) Seal of Acceptance for Pet Oral Care Water Additive

GlobeNewswire April 7, 2022

IIROC Trading Halt - KNE

Canada NewsWire April 7, 2022

Kane Biotech Appoints Dr. Gregory Schultz as Chief Scientific Officer

GlobeNewswire April 5, 2022

Kane Biotech Announces Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire March 24, 2022

Kane Biotech (TSXV:KNE) completes safety studies for DispersinB

Caroline Egan  March 22, 2022

Kane Biotech Successfully Completes Safety and Biocompatibility Studies for DispersinB® Wound Gel in Preparation for Human Clinical Trials

GlobeNewswire March 22, 2022

Kane Biotech to Release Fourth Quarter and Full Year 2021 Financial Results on March 24 - Conference Call to Follow

GlobeNewswire March 17, 2022

Kane Biotech (TSXV:KNE) announces $1M private placement

Trevor Abes  March 15, 2022

Kane Biotech Announces Private Placement Offering

GlobeNewswire March 15, 2022

Kane Biotech (TSXV:KNE) partners with universities for DispersinB study

Caroline Egan  February 10, 2022

Kane Biotech Announces New Collaboration Agreements for Prosthetic Joint Infection, expanding its DispersinB® applications

GlobeNewswire February 10, 2022

Kane Biotech (TSXV:KNE) wound care commercialization to be a key focus in 2022

Brieanna McCutcheon  January 20, 2022

Wound Care Commercialization to be a Key Company Focus in 2022

GlobeNewswire January 20, 2022

Kane Biotech Announces Third Quarter 2021 Financial Results

GlobeNewswire November 16, 2021